Abstract

Pulmonary mucormycosis is an opportunist fungal infection with high mortality. Posaconazole, an azole antifungal which has a proven efficacy against zygomycetes in vitro, has been shown to be useful as salvage therapy in various studies. We reported herein  a lymphoma patient with persistent febrile neutropenia treated for invasive aspergillosis who developed pulmonary mucormycosis subsequently,  and shared our experience on his treatment using posaconazole as salvage therapy following amphothericin B, which is thought to enhance survival because of the positive outcome achieved.